& Board of Directors
Imhotex is managed by a team of experienced drug development professionals.
David J. Grainger
After spending 15 years at Cambridge University leading an internationally-recognised laboratory investigating the causes of coronary heart disease, David founded Funxional Therapeutics, where he became the Chief Scientific Officer, developing FX125L, a novel anti-inflammatory agent for the treatment of asthma and other diseases with a chronic inflammatory component. Following the sale of FX125L in July 2012, David joined Index Ventures as a Venture Partner, where he was responsible for the creation of a number of biotech companies including XO1 (which was sold to Janssen Pharmaceuticals in 2015), Morphogen-IX, Critical Pressure and Divide & Conquer. In February 2016, David co-founded Medicxi a spin-out managing the legacy life sciences portfolio of Index Ventures. Here, he holds the role of Chief Scientific Advisor. In 2018, David and Medicxi co-founded The Foundation Institute of 21st Century Medicine (C21Med) to translate the best science into a pipeline of novel drug candidates and create new life science companies.
Robert W. Schroff
Chief Operating Officer
Bob has more than 35 years experience developing a range of drug product candidates in both large and small companies. He was VP Research and Development at Funxional Therapeutics, where he was responsible for guiding FX125L from discovery through to Phase 2 clinical trials. Bob was Chief Operating Officer at XO1, Stealthyx and SuperX and is presently Chief Operating Officer at Critical Pressure Ltd. Bob is responsible for all aspects of development at Imhotex.
Board of Directors
David J. Grainger
Executive Chairman, Imhotex
Chief Scientific Advisor, Medicxi
Francesco de Rubertis